|
|
|
|
||
Nivolumab/Cabozantinib Continues to Showcase Deep, Durable Responses in Advanced RCCKieth S post.... "Nivolumab plus cabozantinib continued to significantly improve overall response rate vs sunitinib in patients with previously untreated, advanced renal cell carcinoma, with meaningful response outcomes observed irrespective of dose modifications with cabozantinib and fewer responders in the doublet arm requiring subsequent treatment." |
return to message board, top of board |